# Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment

> **NCT01527929** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 25 (actual)

## Conditions studied

- Neoplasm Malignant

## Interventions

- **DRUG:** Cabazitaxel XRP6258

## Key facts

- **NCT ID:** NCT01527929
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01527929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01527929, "Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01527929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*